RTTNews | Aug 31, 2021 08:11AM EDT

08:10 Tuesday, August 31, 2021 (RTTNews.com) - Jazz Pharmaceuticals plc (JAZZ) announced the Health Canada approval and availability of Sunosi for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Sunosi is a dopamine and norepinephrine reuptake inhibitor. The approval of Sunosi is based on data from a phase 3 clinical program which enrolled over 1,500 adults in four randomized placebo-controlled studies.

In 2014, the company acquired a license to develop and commercialize Sunosi from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to Sunosi, excluding certain jurisdictions in Asia.

Read the original article on RTTNews ( https://www.rttnews.com/3222159/jazz-pharma-announces-health-canada-approval-of-sunosi-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved